Alamar Biosciences (ALMR) Morgan Stanley 24th Annual Global Healthcare Conference summary

Market opportunity and industry trends

• Proteomics is experiencing rapid growth due to advances in multiplex panels and the ability to translate discoveries into diagnostics, addressing previously unmet needs in disease characterization and early detection.

• The advanced proteomics research market is valued at $3.7 billion today, projected to reach $11 billion, with clinical diagnostics expected to grow from $400 million to $9 billion by 2035, driven by applications like Alzheimer's disease.

• Multiplex testing is seen as the future for chronic disease diagnostics, enabling broader applications such as early detection and risk prediction.

Technology platform and differentiation

• The precision proteomics platform uniquely combines ultra-high sensitivity, high specificity, high multiplex capability, broad range, and seamless automation, covering the full customer journey from discovery to diagnostics.

• The NULISA platform offers unmatched sensitivity and multiplexing in a fully automated workflow, critical for both research and clinical applications.

• Proprietary chemistry and trade secrets provide a strong competitive moat, with a 10,000-fold improvement in signal-to-noise ratio and robust IP protection.

Commercial strategy and customer journey

• Customers typically begin with a TAP program, receiving high-quality data before purchasing instruments, then expand usage and adopt additional panels and instruments over time.

• Biopharma customers tend to purchase additional instruments quickly for higher throughput, while academic core labs maximize instrument utilization before expanding.

• Most new instrument placements are to new customers, with growing traction from CROs indicating future demand.